Background: Promoter methylation of tumour suppressor genes (TSGs) CDKN2A, CDKN2B and CDH13 has been reported in ovarian cancer. However, the clinicopathological characteristics and prognostic role of CDKN2A, CDKN2B and CDH13 promoter methylation in ovarian carcinoma remained unclear. Methods: The pooled odds ratio (OR) or hazard ratios (HRs) with their 95% confidence intervals (95% CIs) were calculated in this meta-analysis. The Cancer Genome Atlas data were obtained to confirm the role of CDKN2A, CDKN2B and CDH13 methylation in ovarian cancer. Results: CDKN2A, CDKN2B and CDH13 promoter methylation was higher in ovarian cancer than in normal ovarian tissues. CDH13 promoter methylation was correlated with tumour histology (serous vs. non-serous type: OR = 0.33, p = 0.031). CDKN2A promoter methylation was not linked to overall survival (OS), but it was correlated with a poor prognosis in progression-free survival (HR = 1.55, p = 0.004). TCGA data showed no correlation between CDKN2A, CDKN2B and CDH13 methylation and OS as well as disease-free survival (DFS). Conclusions: CDKN2A, CDKN2B and CDH13 promoter methylation may correlate with the increased risk of ovarian cancer. CDKN2A promoter methylation may be an independent prognostic biomarker for predicting progression-free survival.

中文翻译：

---

CDKN2A，CDKN2B和CDH13启动子甲基化在卵巢癌中的临床和预后影响：一项使用荟萃分析和TCGA数据进行的研究。

背景：已经报道了卵巢癌中肿瘤抑制基因（TSG）CDKN2A，CDKN2B和CDH13的启动子甲基化。然而，CDKN2A，CDKN2B和CDH13启动子甲基化在卵巢癌中的临床病理特征和预后作用仍不清楚。方法：在本荟萃分析中计算出合并的优势比（OR）或危险比（HRs）及其95％置信区间（95％CI）。获得了癌症基因组图谱数据，以确认CDKN2A，CDKN2B和CDH13甲基化在卵巢癌中的作用。结果：卵巢癌中CDKN2A，CDKN2B和CDH13启动子甲基化程度高于正常卵巢组织。CDH13启动子甲基化与肿瘤组织学相关（浆液型与非浆液型：OR = 0.33，p = 0.031）。CDKN2A启动子甲基化与总体生存率（OS）无关，但它与无进展生存期预后不良相关（HR = 1.55，p = 0.004）。TCGA数据显示CDKN2A，CDKN2B和CDH13甲基化与OS和无病生存期（DFS）之间无相关性。结论：CDKN2A，CDKN2B和CDH13启动子甲基化可能与卵巢癌风险增加有关。CDKN2A启动子甲基化可能是预测无进展生存期的独立预后生物标志物。